H.C. Wainwright analyst Edward White raised the firm’s price target on Dynavax to $29 from $28 and keeps a Buy rating on the shares. The analyst cites higher revenue estimates
H.C. Wainwright analyst Edward White raised the firm’s price target on Dynavax to $29 from $28 and keeps a Buy rating on the shares. The analyst cites higher revenue estimates
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dynavax (DVAX – Research Report) and EDAP TMS (EDAP – Research Report) with bullish sentiments.
Dynavax (DVAX)
JMP Securities analyst Roy Buchanan reiterated a Buy rating on Dynavax today and set a price target of $29.00. The company’s shares closed last Thursday at $12.44.
According to TipRanks.com, Buchanan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Dynavax has an analyst consensus of Strong Buy, with a price target consensus of $25.50, which is a 103.8% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.
See today’s best-performing stocks on TipRanks >>
EDAP TMS (EDAP)
In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on EDAP TMS, with a price target of $10.00. The company’s shares closed last Thursday at $6.05.
According to TipRanks.com, Takkinen is a 4-star analyst with an average return of
Currently, the analyst consensus on EDAP TMS is a Moderate Buy with an average price target of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DVAX:
In a report released yesterday, Paul Choi from Goldman Sachs maintained a Hold rating on Dynavax (DVAX – Research Report), with a price target of $20.00. Paul Choi has given
Dynavax (DVAX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Phil Nadeau from TD Cowen maintained a Buy rating on the stock
HEPLISAV-B® 2023 net product revenue grew 69% year-over-year to $213 million Achieved market leader status in key segments retail pharmacy and IDNs in 2023 2024 HEPLISAV-B net product revenue expected to